9 completed, 6 active not recruiting, 5 terminated, 2 recruiting. 24 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 24 | Completed 9, Active not recruiting 6, Terminated 5, Recruiting 2, Unknown 2 |
| Phase 2 | 8 | Active not recruiting 2, Completed 2, Terminated 2, Unknown 2 |
Follow Metastatic Prostate Carcinoma: new trials by email Literature Review of Metastatic Prostate Carcinoma trials Research Report on Metastatic Prostate Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Biopsy, Bone Scan, Computed Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 3 | 2024-12-19 | 2026-08-07 |
| PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Biopsy, Biospecimen Collection - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Recruiting | City of Hope Medical Center | 21 | 2024-10-09 | 2026-08-21 |
| Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy Image Guided Biopsy - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 30 | 2024-04-26 | 2026-06-15 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Terminated | Rahul Aggarwal | 2 | 2021-08-10 | 2025-05-20 |
| DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers Ipilimumab, Valemetostat - Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 65 | 2020-08-20 | 2026-05-20 |
| Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 9 | 2020-04-16 | 2022-09-21 |
| PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Cyclophosphamide, Fludarabine - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 14 | 2019-08-20 | 2026-06-02 |
| Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer Enzalutamide, Venetoclax - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | Roswell Park Cancer Institute | 10 | 2019-08-02 | 2023-10-16 |
| 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Lutetium Lu 177-PSMA-617, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | University of California, San Francisco | 43 | 2019-05-10 | 2025-02-25 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 23 | 2018-09-24 | 2026-04-29 |
| Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies Avelumab, Ivuxolimab, Radiation Therapy - Advanced Malignant Solid Neoplasm, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 173 | 2017-08-02 | 2026-10-23 |
| Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer Enzalutamide, Indomethacin - Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 1 / Phase 2 | Unknown | Mamta Parikh | 38 | 2017-01-17 | 2023-11-29 |
| Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer Enzalutamide, Niclosamide - Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma | Phase 1 | Completed | University of California, Davis | 6 | 2017-01-09 | 2026-05-06 |
| A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients SHR3680 - Hormone Refractory Prostate Cancer, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 197 | 2016-04-12 | 2020-05-13 |
| Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Carboplatin, Docetaxel, Laboratory Biomarker Analysis - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Terminated | University of Washington | 28 | 2016-02-29 | 2021-10-01 |
| Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer Enzalutamide, Laboratory Biomarker Analysis, Niclosamide - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | University of Washington | 5 | 2015-12-31 | 2018-04-18 |
| Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression Enzalutamide, Ribociclib, Laboratory Biomarker Analysis - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 52 | 2015-12-01 | 2026-04-22 |
| Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Cabazitaxel, Enzalutamide, Laboratory Biomarker Analysis - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1 / Phase 2 | Active not recruiting | OHSU Knight Cancer Institute | 37 | 2015-08-13 | 2026-09-15 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer Pembrolizumab, pTVG-HP Plasmid DNA Vaccine - Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone | Phase 1 / Phase 2 | Completed | University of Wisconsin, Madison | 66 | 2015-07-01 | 2023-08-01 |
Showing 20 of 24. Sign in to see all of them.
Prostatic Neoplasms (24) · Neoplasm Metastasis (4) · Carcinoma, Renal Cell (3) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Transitional Cell (2) · Lung Neoplasms (2) · Melanoma (2) · Ovarian Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Medullary (1) · Carcinoma, Non-Small-Cell Lung (1) · Clear-cell metastatic renal cell carcinoma (1)
Genital Diseases (24) · Genital Diseases, Male (24) · Genital Neoplasms, Male (24) · Male Urogenital Diseases (24) · Neoplasms (24) · Neoplasms by Site (24) · Prostatic Diseases (24) · Urogenital Diseases (24) · Urogenital Neoplasms (24) · Neoplastic Processes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Adenocarcinoma (3) · Breast Diseases (3) · Carcinoma (3)
Magnetic Resonance Spectroscopy (6) · enzalutamide (6) · Biopsy (3) · Specimen Handling (3) · Carboplatin (2) · Docetaxel (2) · Niclosamide (2) · Radiation (2) · Sirolimus (2) · XRP6258 (2) · cabazitaxel (2) · pembrolizumab (2) · 68Ga-DKFZ-PSMA-11 (1) · AZD8186 (1) · Androgen Antagonists (1)
M.D. Anderson Cancer Center (3) · Roswell Park Cancer Institute (3) · City of Hope Medical Center (2) · Jonsson Comprehensive Cancer Center (2) · National Cancer Institute (NCI) (2) · University of Washington (2) · Jiangsu HengRui Medicine Co., Ltd. (1) · Mamta Parikh (1) · OHSU Knight Cancer Institute (1) · Rahul Aggarwal (1) · Rutgers, The State University of New Jersey (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Stanford University (1) · University of California, Davis (1) · University of California, San Francisco (1)
United States (23) · China (1)
Rahul Aggarwal, MD (2) · Tanya B Dorff (2) · Alison M Schram (1) · Ana Aparicio (1) · Andrei Iagaru (1) · Aung Naing (1) · Chong-Xian Pan (1) · Dingwei Ye, M.D. (1) · Douglas G McNeel, MD PhD (1) · Gurkamal Chatta (1) · Haiying Cheng (1) · Isaac Kim (1) · Jeremie Calais (1) · Johannes Czernin (1) · Julie N Graff (1)
PMID 29856824, PMID 29876010, PMID 30700328, PMID 31515154, PMID 35241087, PMID 35277461, PMID 35405009, PMID 36351402, PMID 37902861, PMID 37922930, PMID 38867077, PMID 40132910, PMID 40139261, PMID 40939237, PMID 41315064, PMID 41378786, PMID 41646361, PMID 41698328, PMID 42847673
P30CA015704 (2), P30CA093373 (2), P50CA097186 (2), P30CA016056 (1), P30CA016672 (1), P30CA033572 (1), P30CA072720 (1), P30CA124435 (1), R01CA158318 (1), R01CA229354 (1), R01MH115043 (1), UM1CA186691 (1)